 | • レポートコード：MRC2108A031 • 出版社/出版日：Mordor Intelligence / 2021年7月26日 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品 |
| Single User | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,110,000 (USD7,500) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社は、2020年に512.6億ドルであった抗ウイルス治療薬の世界市場規模が、2021年から2026年の間に年平均4.76％成長し、2026年までに677.6億ドルに達すると予測しています。本調査レポートは、世界の抗ウイルス治療薬市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、薬剤タイプ別（ヘルペス用抗ウイルス薬、肝炎用抗ウイルス薬、HIV用抗ウイルス薬、インフルエンザ用抗ウイルス薬、その他抗ウイルス薬）分析、流通チャネル別（病院薬局、独立薬局＆ドラッグストア、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、市場機会/将来の見通しなどを掲載しています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・抗ウイルス治療薬の世界市場規模：薬剤タイプ別（ヘルペス用抗ウイルス薬、肝炎用抗ウイルス薬、HIV用抗ウイルス薬、インフルエンザ用抗ウイルス薬、その他抗ウイルス薬） ・抗ウイルス治療薬の世界市場規模：流通チャネル別（病院薬局、独立薬局＆ドラッグストア、オンライン薬局） ・抗ウイルス治療薬の世界市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（AbbVie Inc.、AstraZeneca、Boehringer Ingelheim、Bristol-Meyrs Squibb Company、Cipla Inc.、Dr. Reddy's Laboratories Ltd.、F. Hoffmann-La Roche Ltd、GlaxoSmithKline PLC、Johnson & Johnson、Merck & Co. Inc.、Novartis AG、Pfizer Inc.、Sanofi SA、Gilead Sciences, Inc.） ・市場機会/将来の見通し |
The anti-viral therapeutics market was valued at USD 51.26 billion in 2020, and it is expected to reach USD 67.76 billion in 2026, by registering a CAGR of 4.76% during the forecast period.
The sudden outbreak of the COVID-19 pandemic has made an optimistic effect on the global antiviral therapy market growth. The strong growth of the market due to the COVID-19 is mainly attributed to the increasing focus of the major market players for the treatment development of COVID-19 drugs. For instance, in May 2020, Cipla and Gilead Sciences entered a partnership alliance to develop and commercialize the investigational medicine that is being used for the treatment of COVID-19 affected patients. The research and development activities on the potential lead molecules are boosting the market and are expected to do so even in the forecast period.
The anti-viral therapeutics market is expected to witness an upsurge in growth mainly due to the increasing research and development investment by private and public companies for antiviral drugs. For instance, as per Clinical Trials.gov as of 3rd, February 2020, there were currently 1,126 clinical trials going on for anti-viral therapeutics. These trials are mainly driven by the growing burden of viral infections among populations. According to The Joint United Nations Programme on HIV/AIDS (UNAIDS), approximately 38.0 million people globally had HIV in 2019. Of these, an estimated number of 1.7 million people were newly infected with HIV in 2019. In addition to that, over 690,000 people died from AIDS-related illnesses in 2019.
Furthermore, the Joint United Nations Programme on HIV and AIDS also estimated that as of June 2020, 26.0 million were accessing antiretroviral therapy, whereas in 2019, about 25.4 million people were receiving antiretroviral therapy up from 6.4 million in 2009. This data suggested that access to antiviral therapeutic drugs is continuously increasing which is the major factor propelling the market growth.
Moreover, strong research and development pipelines of the major players coupled with, increasing product launches, are of the key drivers in the antiviral therapeutics market growth. For instance, in November 2019, Atriva Therapeutics GmbH, a biopharmaceutical company focused on the development of host-targeting antiviral therapies, successfully concluded the top-line results of its Phase I clinical trial for its lead drug candidate ATR-002. The company initiated the Phase I clinical trial with its ATR-002 in May 2019, as a novel host-targeted approach to treating influenza virus infections. Anti-viral therapeutics are currently commercially available for diseases, like influenza, hepatitis C, chickenpox, papilloma, and AIDS.
Additionally, there is increasing development in molecular biology promoting drug development and the growing adoption of nucleoside and nucleotide analogs as first-line anti-virals. Based on the current development pipeline in the market many small molecule-based anti-viral drugs are anticipated to receive product approvals in the future, propelling the market growth to enormous heights. For instance, in February 2018, Gilead Sciences, Inc. received the United States Food and Drug Administration (FDA) approval for its Biktarvy, once-daily single-tablet regimen for the treatment of HIV-1 infection. However, the high cost of antiviral drug treatment can hinder the market growth in developing regions.
Key Market Trends
Influenza Anti-viral Drugs Segment is Expected to Hold Significant Market Share Over the Forecast Period
The major reason attributed to the growth of Influenza Anti-viral Drugs segment is the prevalence of influenza worldwide and an increasing number of drug launches coupled with several drugs currently in the pipeline.
Globally, the current COVID-19 situation has increased the surveillance of the influenza virus among the population. Various countries along with testing for COVID-19 in the test sample given by the symptomatic patient are also testing for influenza virus, which has increased the diagnosis of the disease.
In addition, the World Health Organization (WHO) is also encouraging countries to continue routine influenza surveillance, test samples from influenza surveillance sites for influenza and SARS-CoV-2 viruses where resources are available, and report epidemiological and laboratory information in a timely manner to established regional and global platforms. The increased diagnosis of influenza is expected to affect the market in a positive way, as more patients will reach out for antiviral therapies after being diagnosed. Overall, the COVID-19 pandemic is anticipated to have a positive impact on the market studied.
In October 2020, the United States Food and Drug Administration (FDA) approved Veklury (remdesivir), the first drug approved to treat COVID-19, for use in adults and pediatric patients who are 12 years of age and older and weighing at least 40 kg (about 88 pounds) requiring hospitalization.
According to the estimates published by the Centers for Disease Control and Prevention (CDC), in the year 2018–2019, an estimated 35.5 million people got sick from influenza, of these 16.5 million people went to a health care provider for their illness. In the year 2018-19, about 490,600 hospitalizations and 34,200 deaths occurred from influenza.
In order to cater to the large unmet needs in the market, the players are focusing on their research and development with potential candidates. For instance, in June 2019, Cidara Therapeutics Inc., a biotechnology company focused on developing novel anti-infectives, reported new data from studies of CB-012, its Cloudbreak antiviral Fc-conjugate (AVC) candidate for influenza. The novel launch of products from this strong pipeline is anticipated to propel market growth over the forecast period.
North America Dominates the Market and Expected to do Same in the Forecast Period
The North America is anticipated to dominate the anti-viral therapeutics market, due to the presence of well-established market players along with the growing prevalence of HIV and other viral infections.
Respiratory failure due to COVID-19 has caused widespread mortality, creating an urgent need for effective treatments and a long-term need for ant-ivirals for future emergent coronaviruses. For instance, according to a research study by Angela Holly Villamagna et al., published in Frontiers in Medicine Journal December 2020, the study results found that in United States for the treatment of respiratory viral infections due to COVID-19 effective antiviral therapy and prevention of future emergent coronaviruses there is a need for continue research and development activities in the development of new effective antiviral therapeutics.
According to the Center for Disease Control (CDC) 2018, estimates about 2.4 million people had hepatitis C in the United States, and approximately 850,000 people had hepatitis B. In addition as per above source, 67% of persons infected with hepatitis B virus do not know they have the virus.
Furthermore, the growth of the market in North America region is also attributed to the increasing investment in research and development by the major players and the robust drug approval by the United States Food and Drug Administration (FDA) in recent years. For instance, in August 2020, ViiV Healthcare, the global specialist HIV company headquartered in the United States, received the United State Food and Drug Administration (FDA) approval for its Dovato, as a complete regimen for the treatment of HIV-1 infection to replace the current antiretroviral (ARV) regimen in adults who are virologically suppressed.
In addition, to fuel the market growth in the current pandemic situation the federal government is providing support funds to pharmaceutical companies to help them to strengthen their clinical development pipelines. For instance, in July 2020, Novavax and Regeneron received USD 2 billion funding from the United States federal government to manufacture drugs and vaccines against COVID-19. Thus, owing to above mentioned factors it is expected to drive market growth in North America region during the forecast period.
Competitive Landscape
The Anti-Viral Therapeutics Market is moderately competitive. Some of the major players in the anti-viral therapeutics market are AbbVie Inc., GlaxoSmithKline Plc, Bristol-Myers Squibb Company, Johnson & Johnson, Merck and Co Inc., The anti-viral therapeutics market is a fast-growing market. The major players of the market are adopting organic as well as inorganic strategies to survive and expand in the market. Moreover, the key players are focusing on increasing United States Food and Drug Administration (FDA) approvals and product launches in order to leverage current and future market opportunities.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Initiatives to Curb Viral Diseases by Public and Private Companies
4.2.2 Increasing Research and Development Investment
4.2.3 Growing Burden of HIV Infection
4.3 Market Restraints
4.3.1 High Cost of Antiviral Drug Treatment
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug Type
5.1.1 Herpes Anti-viral Drugs
5.1.2 Hepatitis Anti-viral Drugs
5.1.3 HIV Anti-viral Drugs
5.1.4 Influenza Anti-viral Drugs
5.1.5 Other Anti-viral Drugs
5.2 By Distribution Channel
5.2.1 Hospital Pharmacy
5.2.2 Independent Pharmacy and Drug Store
5.2.3 Online Pharmacy
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AbbVie Inc.
6.1.2 AstraZeneca
6.1.3 Boehringer Ingelheim
6.1.4 Bristol-Meyrs Squibb Company
6.1.5 Cipla Inc.
6.1.6 Dr. Reddy’s Laboratories Ltd.
6.1.7 F. Hoffmann-La Roche Ltd
6.1.8 GlaxoSmithKline PLC
6.1.9 Johnson & Johnson
6.1.10 Merck & Co. Inc.
6.1.11 Novartis AG
6.1.12 Pfizer Inc.
6.1.13 Sanofi SA
6.1.14 Gilead Sciences, Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS